December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Antonio Passaro: An intense yet incredibly rewarding day in Oporto
Apr 21, 2024, 18:13

Antonio Passaro: An intense yet incredibly rewarding day in Oporto

Antonio Passaro, Medical Director with Highly Specialized Position at IEO European Institute of Oncology, shared a post on LinkedIn:

“Yesterday was an intense yet incredibly rewarding day in Oporto.
In the morning, I had the privilege of participating in the 5TH Lung Cancer Course hosted by the Portuguese Society of Pulmonology, where I delved into the challenges of immunotherapy in the early stages of Non-small-cell lung cancer (NSCLC).

Later in the day, I attended the ProLung 2024 event, where I enjoyed discussing EGFR mutant disease, from bench to bedside.
It was fantastic to share insights and explore the myriad updates (FLAURA2, MARIPOSA, MARIPOSA-2, HERTHENA-LUNG1, and more) revolutionizing the treatment landscape for this biomarker-driven disease.
Grateful for the enriching experiences and the opportunity to contribute to advancing patient care!

Thanks to João Ramalho Carvalho, maria fernandes for the invitations!”

Antonio Passaro: An intense yet incredibly rewarding day in Oporto

Source: Antonio Passaro/LinkedIn


About OncoDaily 

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we“.